Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates Decrease
10 Novembre 2006 - 2:15PM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 10 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced the presentation
of updated safety results from its Phase 1/2 trial of PDX
(pralatrexate) in patients with relapsed or refractory
non-Hodgkin's lymphoma (NHL) and Hodgkin's disease. Owen O'Connor,
M.D., Ph.D., Head of the Laboratory of Experimental Therapeutics
for Lymphoproliferative Malignancies, Lymphoma and Development
Chemotherapy Services, Memorial Sloan-Kettering Cancer Center
(MSKCC) and the study's principal investigator, presented the
findings in a poster presentation today at the 2006 EORTC-NCI-AACR
International Conference on Molecular Targets and Cancer
Therapeutics. Dr. O'Connor and colleagues reviewed safety data from
the on-going Phase 1/2 trial, designed to determine the maximum
tolerated dose (MTD), dose limiting toxicities and preliminary
efficacy of PDX in patients with relapsed or refractory aggressive
lymphomas. Patients initially enrolled in the study were treated
with 135 mg/m2 of PDX administered without folic acid and vitamin
B12 supplementation every other week. The protocol was amended in
July 2004 to explore a weekly dosing schedule and the MTD was
ultimately defined as 30 mg/m2 of PDX administered weekly for six
weeks in a seven week cycle. Results of the analysis indicate that
a higher incidence of stomatitis was observed in patients with
marked elevations in pre-treatment homocysteine (Hcy) and
methylmalonic acid (MMA). Comparatively little to no increase in
stomatitis occurred in patients with Hcy and MMA less than 10 mM
and 200 nM respectively. Patients with elevated Hcy and MMA who
developed stomatitis with PDX did not develop advanced grade
stomatitis after normalization of their Hcy and MMA with folic acid
and vitamin B12 supplementation. Subsequent to this finding, all
enrolled patients have received pre-treatment with vitamin
supplementation of vitamin B12 and folic acid, and normalization of
Hcy and MMA levels has mitigated the incidence of stomatitis.
"These findings illustrate the existence of chemical markers that
seem to allow us to dose in a manner that prevents the occurrence
of toxicities commonly associated with this class of agents," said
Dr. O'Connor. PDX is currently the subject of a pivotal Phase 2,
international, multi-center, open-label, single-arm study called
PROPEL that will seek to enroll 100 evaluable patients with
relapsed or refractory PTCL who have progressed after at least one
prior treatment. The primary endpoint of the study is objective
response rate (complete and partial response). Secondary endpoints
include duration of response, progression-free survival and overall
survival. Dr. O'Connor is the international chair of this study. In
August 2006, the Company announced that it reached agreement with
the FDA under the Special Protocol Assessment process on the design
of this pivotal Phase 2 trial. The Company currently anticipates
that patient enrollment at approximately 35 centers in the U.S.,
Canada and Europe will be completed by the third quarter of 2008.
In July 2006, the FDA awarded orphan drug designation to PDX for
the treatment of patients with T-cell lymphoma. About PDX
(pralatrexate) PDX is a novel, small molecule chemotherapeutic
agent that inhibits dihdrofolate reductase (DHFR), a folic acid
(folate) dependent enzyme involved in the building of DNA and other
processes. PDX was rationally designed for improved transport into
tumor cells via the reduced folate carrier (RFC-1), and greater
intracellular drug retention. These biochemical features, together
with preclinical data in a variety of tumors, suggest that PDX has
an enhanced potency and improved toxicity profile relative to
methotrexate and other related DHFR inhibitors. About Peripheral
T-cell Lymphoma Peripheral T-cell lymphomas, or PTCLs, are a
biologically diverse and uncommon group of blood cancers that
account for approximately 10% to 15% of all cases of non-Hodgkin's
lymphoma, or about 6,700 patients annually. The average five year
survival rate for PTCL patients is approximately 25%. There are
currently no pharmaceutical agents approved for use in the
treatment of relapsed or refractory PTCL. About Allos Therapeutics,
Inc. Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development: EFAPROXYN
(efaproxiral), a radiation sensitizer currently under evaluation in
a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer, and PDX (pralatrexate), a novel, next
generation antifolate currently under evaluation in a pivotal Phase
2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted
chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com/. Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements concerning the potential safety and
efficacy of PDX for the treatment of patients with aggressive
lymphomas, including PTCLs; the Company's projected timeline for
the completion of patient enrollment in the PROPEL trial and other
statements that are other than statements of historical facts. In
some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "expects," "intends,"
"plans," "anticipates," "believes," "estimates," "predicts,"
"projects," "potential," "continue," and other similar terminology
or the negative of these terms, but their absence does not mean
that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others: that clinical trials may not demonstrate the safety
and efficacy of PDX for the treatment of peripheral T-cell
lymphoma; that the Company may experience difficulties or delays in
its clinical trials, whether caused by adverse events,
investigative site initiation rates, patient enrollment rates,
regulatory issues or other factors; that the Company may be unable
to obtain the regulatory approvals necessary to conduct additional
clinical trials; that data from preclinical studies and clinical
trials may not necessarily be indicative of future clinical trial
results; and the risk that the Company may lack the financial
resources and access to capital to fund future clinical trials for
PDX or any of its other product candidates. Additional information
concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking
statements is contained in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December
31, 2005, and in the Company's other periodic reports and filings
with the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227, or
cell, +1-303-478-3340, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024